Lucida Medical is a UK medical technology company developing artificial intelligence to help clinicians detect prostate cancer earlier and more accurately from MRI. Its flagship solution, Pi™ (Prostate Intelligence), analyses prostate MRI scans to highlight suspicious lesions and generate risk scores that support radiologists’ decisions. CE-certified and deployed across NHS hospitals and Europe, Pi™ has been trained and validated on thousands of patient scans. Clinical research across multiple NHS Trusts has shown the system can detect clinically significant prostate cancer with performance comparable to expert radiologists.
Lucida Medical: Venture Capital Funding History
Lucida Medical
Lucida Medical
- Health
- Cambridge, United Kingdom
- £8.7m
- lucidamedical.com
- Update Information
More venture news
- 5 Nov 2026

NayaraNayara closes a pre-seed round led by SFC Capital to support patients between appointments with AI companions
Pre-seedHealth - 4 Nov 2026

SurghiveSurghive raises a £320k seed round led by SFC Capital to train surgeons on any robotic surgery system
SeedHealth - 3 Nov 2026

1nhaler1nhaler lands a £2m follow-on round led by Archangels to test its pop-up cardboard asthma inhaler in patients
Follow-onHealth
